Pharmaceutical drugs: suspected anti-competitive agreements
The CMA is investigating alleged anti-competitive agreements in the pharmaceutical sector under Chapter I CA98 (case reference: 50511-1).
Case timetable
| Date | Action |
|---|---|
| 8 October 2021 | Case closed on administrative priority grounds |
| 1 January 2021 | Following the end of the EU Exit Transition Period on 31 December 2020, the CMA’s investigation continues on the basis of the Chapter I prohibition in the Competition Act 1998 only (see CMA Guidance on the functions of the CMA after the end of the Transition Period) |
| 20 July 2020 to Autumn 2021 (estimate) | Considering written and oral representations on the Statement of Objections |
| 7 April to 20 July 2020 | Case paused in order to reallocate resources to ensure that the CMA is able to focus on urgent work during the coronavirus (COVID-19) pandemic |
| February 2020 to April 2020 | Receipt of written representations on the Statement of Objections |
| July 2019 | Statement of Objections issued |
| Q2 2019 | Decision on whether to issue a Statement of Objections for certain alleged anti-competitive agreements and/or concerted practices and certain parties |
| July 2018 to Q1 2019 | Further investigation including further information gathering in relation to certain alleged anti-competitive agreements and/or concerted practices and certain parties. CMA analysis and review of information gathered. |
| October 2017 to June 2018 | Initial investigation and information gathering. CMA analysis and review of information gathered. |
| October 2017 | Investigation opened |
Change log
The following changes have been made to the case timetable since it was first published:
| Date of change | Reason for change | Change made to timetable |
|---|---|---|
| 23 April 2021 | Additional time needed to consider parties’ responses to the Statement of Objections | End date for CMA consideration of written and oral representations on the Statement of Objections changed from Spring 2021 to Autumn 2021 |
| 20 July 2020 | Case resumed | Date for CMA final decision on case outcome changed to Spring 2021 |
| 7 April 2020 | Case paused in order to reallocate resources to ensure that the CMA is able to focus on urgent work during the coronavirus (COVID-19) pandemic | Timetable paused |
| 28 March 2019 | Additional time needed to analyse information | Date for CMA decision on whether to issue a Statement of Objections changed from Q1 2019 to Q2 2019. |
Case closure
On 8 October 2021, the CMA closed its investigation into suspected breaches of competition law relating to the supply of nitrofurantoin capsules on administrative priority grounds.
The reasons for closing the investigation are set out in the CMA’s case closure statement.
- (8.10.21)
Statement of objections
25 July 2019: The CMA issued a Statement of Objections alleging that AMCo (now Advanz Pharma Services (UK) Limited), Alliance Healthcare (Distribution) Limited, Morningside Healthcare Limited and Morningside Pharmaceuticals Limited (Morningside), breached UK and EU competition law by participating in anti-competitive agreements and/or concerted practices in relation to the supply of nitrofurantoin 50mg and 100mg capsules in the UK. The CMA also alleges that AMCo disclosed sensitive pricing information to Morningside with the aim of reducing competition between them.
- Press release: Drug firms accused of illegal market sharing in supply of antibiotic (25.7.19)
Notes
-
The investigation is under Chapter I of the Competition Act 1998 (CA98).
-
No conclusion should be drawn that there has been an infringement of competition law at this stage and the recipients of the Statement of Objections will now have the opportunity to respond to the allegations.
-
The CMA will consider any representations it receives before any decision is taken as to whether competition law has in fact been infringed.
-
Changes to the timing of original entries in the case timetable will be made where the estimated timing changes.
Case information
On 10 October 2017, the CMA launched an investigation under Chapter 1 of the CA98 and Article 101 of the TFEU into suspected breaches of competition law by various parties. The investigation relates to alleged anti-competitive agreements and/or concerted practices in relation to generic pharmaceutical products.
Following the end of the EU exit ‘Transition Period’ on 31 December 2020, EU law is no longer being applied in the UK and the CMA will only investigate suspected infringements of UK domestic competition law in relation to conduct from both before and after 31 December 2020.The CMA’s investigation in this case since the end of the Transition Period therefore continues on the basis of the Chapter I prohibition in the Competition Act 1998 only.
Contacts
- Assistant Project Director: Maria Rican-Sevitz (020 3738 6859, maria.rican-sevitz@cma.gov.uk)
- Project Director: Brian Jackson (020 3738 6546, brian.jackson@cma.gov.uk)
- Senior Responsible Officers: Ann Pope (020 3738 6786, ann.pope@cma.gov.uk), Geoff Steadman (020 3738 6311, geoff.steadman@cma.gov.uk)
Updates to this page
Published 12 July 2018Last updated 8 October 2021 + show all updates
-
Case closure summary published and Case timetable updated.
-
Updates to the case timetable and change log published.
-
Case timetable and change log updated.
-
Case paused and timetable updated.
-
Timetable updated.
-
Statement of objections issued.
-
Date for CMA decision on whether to issue a statement of objections changed from Q1 2019 to Q2 2019.
-
First published.